Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients.

ABSTRACT:

Objective

Metabolic associated fatty liver disease (MAFLD) affects nearly a quarter of the world's population. Our study aimed to characterize the gut microbiome and overall changes in the fecal and serum metabolomes in MAFLD patients.

Methods

Thirty-two patients diagnosed with MAFLD and 30 healthy individuals (control group, CG) were included in this study, the basic clinical characteristics and laboratory test results including routine biochemistry, etc. were recorded for all, and their serum and fecal samples were collected. A portion of the fecal samples was subjected to 16S rDNA sequencing, and the other portion of the fecal samples and serum samples were subjected to non-targeted metabolomic detection based on liquid chromatography-mass spectrometry (LC-MS). Statistica

SUBMITTER: Yang L 

PROVIDER: S-EPMC9441872 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature